Sep. 7 at 7:02 PM
$ZVRA
Unidentified Bidders: Market speculation has continuously pointed to at least one other unnamed company quietly evaluating a bid for Zevra. These reports frequently note that a suitor might require a bridge loan to fund the acquisition.
Why Zevra is an Attractive Target
Zevra’s strategic transition into a pure-play rare disease company makes it an appealing acquisition target for larger pharmaceutical firms looking to bolster their pipelines:
Commercial Foundation: The FDA approval & robust launch of MIPLYFFA for Niemann-Pick disease type C (NPC) provides a reliable, long-term commercial revenue stream.
Streamlined Asset Structure: Divesting its entire non-core SDX ADHD portfolio to Commave for
$50 mil, Zevra eliminated a major legal overhead & transformed into a highly focused, clean investment vehicle.
Strong Cash Balance: Zevra maintains a strong capital cushion—holding over
$260 mil in liquidity—making its overall financial health highly stable for potential acquirers.
(cont'd)
